Results 191 to 200 of about 21,074 (263)

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7737-7751, September 2026.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +1 more source

Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. [PDF]

Diabetes Obes Metab
Nauck MA, Punov V, Kang YM, Lim S.
europepmc   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8367-8377, September 2026.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source

Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

AACE Endocrinol Diabetes
Eisa N, Barood O.
europepmc   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8208-8218, September 2026.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Richard T. Liggins, Owen Chan, Michael C. Riddell   +7 more
wiley   +1 more source

Long-Term Outcomes of Metabolic and Bariatric Surgery: Durability of Weight Loss, Metabolic Remission, and the Changing Treatment Landscape. [PDF]

J Metab Bariatr Surg
Kim Y, Kim KH, Lee SH, Moon Y, Oh Y, Seo KW.   +5 more
europepmc   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

The attenuated incretin effect is associated with glucose intolerance in patients with hepatitis B-related acute-on-chronic liver failure. [PDF]

Front Physiol
Li M, Hu H, Liu Y, Wu X, Zhang Y, Li Y, Yang F, Li Y, Lin S.   +8 more
europepmc   +1 more source

Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8378-8389, September 2026.
ABSTRACT Aims The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis.
Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian   +5 more
wiley   +1 more source

Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management

Frontiers in Endocrinology
Kexin Zhang, Kexin Zhang, Xiaodong Sun, Xiaodong Sun, Lixin Li   +4 more
doaj   +1 more source